德琪醫藥-B(06996.HK)公布，在悉尼Bellberry人類研究倫理委員會(HREC)批准ATG-018用於治療晚期實體瘤及血液系統惡性腫瘤患者的I期臨床試驗(ATRIUM試驗)申請後，澳洲藥品管理局(TGA)亦於昨日(22日)發出確認該項目的臨床試驗通知(CTN)。
ATG-018用於共濟失調性毛細血管擴張和Rad3相關(ATR)激酶的口服、強效、選擇性小分子抑制劑。
德琪醫藥-B(06996.HK)實體瘤藥獲澳洲發出確認臨床試驗通知
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.